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Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2 (PIMS-TS) or Multisystem 
Inflammatory Syndrome in Children (MIS-C) is a post COVID-19 multisystem inflammatory syndrome in children and 
adolescents <21 years of age. It is slowly emerging in India with clinical features overlapping with Kawasaki Disease (KD) and 
Toxic Shock Syndrome (TSS). Ten PIMS-TS cases admitted in a pediatric hospital between July and Sept 2020 were compared 
with 19 Kawasaki Disease (KD) patients’ data. The median age of PIMS-TS was 6 years (older to KD), 80% were males. PMS-TS 
cases had high inflammatory markers: CRP, ferritin, interleukin (IL)-6. Other distinct features were lymphopenia, 
hypoalbuminemia, and hyponatremia. Serial measurements of CRP showed high baseline values with subsequent decrease.  
NT-Pro BNP level was extremely elevated; suggestive of cardiac injury. All patients recovered. Laboratory features of PIMS-TS 
present a unique pattern of intense inflammation, and cardiac involvement that is different from features of pre COVID-19 KD. 
CRP remains a useful, inexpensive marker for PIMS-TS diagnosis and clinical progression. 
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The profiling of Coronavirus Disease 2019 
(COVID-19) symptoms in the pediatric cohort tells 
that the manifestation of the disease differs 
considerably from the adult spectrum
1,2
. While the 
Centre for Disease Control and Prevention (CDC) in 
the US reported that children account for only 8.6% 
of confirmed COVID-19 cases, there are no 
prevalence data in India
3,4
. Some children require 
hospitalization and intensive care as a result of 
multisystem inflammatory conditions (MIC) that 
develop post COVID-19 several weeks after 
exposure
5
. This COVID-19 associated multisystem 
inflammatory syndrome in children (MISC) and 
adolescents is referred to as Pediatric Inflammatory 
Multisystem Syndrome temporarily associated with 
SARS-CoV-2 (PIMS-TS)
6
 and later labeled as MIS-C 
(a multisystem inflammatory syndrome in children) 
associated with COVID-19
7,8
. The disorder emerged 
gradually as observed by pediatricians all around the 
globe in children with unusual febrile illness, elevated 
inflammatory markers and multisystem involvement 
with considerably overlapping features of Kawasaki 
disease (KD) and Toxic Shock Syndrome (TSS), yet 
is quite a distinct entity by itself
9-12
. PIMS-TS has also 
therefore been variably termed as Kawasaki-like 
disease or incomplete Kawasaki disease.  
The association of PIMS-TS with COVID-19 needs to 
be ascertained with a positive test for SARS-Cov-2 
showing the presence of viral RNA by reverse 
transcriptase polymerase chain reaction (RT-PCR), 
antigen, or antibody (Immunoglobulin G), or exposure to 
others with COVID-19 within the four weeks before the 
onset of symptoms. However, the sensitivity and 
specificity of the tests along with the unavailability of 
testing of contacts hampers the establishment of an 
association for all practical cases. Nonetheless, PIMS-TS 
is being rapidly reported by regions greatly affected by 
SARS-Cov-2, including India, with similar trends and 
timelines that point exclusively to the hyperinflammatory 
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, and more recently from Mumbai 
Metropolitan area
17
, paints a clearer picture of the 
new disorder in children, although much remains 
unknown about the pathogenesis and long term 
outcomes. PIMS-TS occurs 2-4 weeks after infection 
with SARS-CoV-2. It is uncommon compared to the 
real prevalence of the infection in adolescents below 
21 years of age. Antibody detection against the virus 
is reasonably common, but the virus per se is detected 
in a much smaller proportion.   
In a nutshell, children present with high grade fever 
lasting for 8-9 days with features of skin rash, mucositis 
and conjunctivitis, vomiting and diarrhea and abdominal 
pain, many of which are similar to features of KD. This 
is accompanied by increased inflammatory markers such 
as C-reactive protein (CRP), ferritin, neutrophil counts, 
and lactate dehyrogenase (LDH). Anemia, lymphopenia, 
hypoalbuminemia and hypercoagulation indices are 
other distinguishing features. Systemic involvement  
of two or more organs is common. Shock, cardiac  
injury shown by high concentrations of troponin and 
brain natriuretic peptides, coronary aneurysms and 
gastro-intestinal findings such as appendicitis  
require intensive care support. The majority of patients 
survive following treatment with immunomodulating 
agents (intravenous immune globulin, glucocorticoids, 




Because PIMS-TS show overlapping clinical features 
with KD, therefore, laboratory features of both PIMS-TS 
and preCOVID-19 KD were explored in this study. 
 
Materials and Methods 
Patients who were admitted to Institute of Child 
Health, Kolkata between July 7 and September 30; 2020 
were included if they (1) were 18 years or younger;  
(2) presented with a clinical syndrome characterized  
by prolonged fever, systemic inflammation, shock,  
end-organ dysfunction, and were diagnosed with  
PIMS-TS or KD; and (3) and were tested for Interleukin 
(IL) -6 and NT Pro Brain Natriuretic Peptide (NT  
Pro BNP) and other inflammatory markers and  
assessed for hematologic parameters, renal, liver, and 
cardiac function. Demographic details and outcome 
assessments of the cases were recorded. Additionally 
historical data of patients of KD were accessed from 
hospital records.  
 
Statistical analysis 
The Student’s t-test, the χ² method, and Fisher’s exact 
test were used for continuous and categorical variables. 
Mann Whitney non-parametric test was used to 
determine differences between non-normal test 
variables. D’Agostino and Pearson omnibus normality 
test was used to determine the distribution of data.  
P <0·05 was considered to determine significance. 
Analysis of data was performed on Medcalc version 8.0, 
Mariakerke, Belgium. 
The Institutional Ethics Committee (ICH/IEC/48/ 
2020 dated 31.07.2020) approved the study with a 
waiver of informed consent. 
 
Results 
Demography and outcome 
Ten patients of PIMS-TS and 3 patients of KD 
admitted during the study period were included. 
Retrospective data of 16 patients of KD who were 
admitted to the hospital earlier in 2019-2020 have 
also been included for comparison. Baseline 
characteristics are provided in (Table 1). PIMS-TS 
patients were older in age (compared to KD). Patients 
were admitted with common symptoms of high-grade 
fever, conjunctivitis, mucositis, edema, erythematous 
rash, vomiting and diarrhoea.  
All the PIMS-TS were negative for the PCR tests 
to detect SARS-CoV-2 virus and all but one patient 
had a positive IgG antibody against SARS-CoV-2. 
This patient had contact with his father who had 
tested positive from the PCR test for SARS-CoV-2. 
Of the 10 PIMS-TS cases, 4 needed PICU support. 
All the PIMS-TS were completely recovered. One of 
the ten PIMS-TS patients was referred for cardiac 
management and was tested for IL-6.  
There was one patient of diagnosed with Systemic 
lupus erythematosus (SLE) was admitted with active 
SARS-CoV-2 infection and is included for 
comparison of laboratory features with PIMS-TS 
which is a post-COVID-19 phenomenon. One of the 3 
KD patients also had active SARS-CoV-2 infection.  
Table 1 — Demographic and outcome in PIMS  
and KD patients 





Age, Years 6 (4-10) 1.3 (0.75-2.2) 0.0002 
Sex, Males (%) 8 (80%) 10 (~50%) 0.23 
Length of Stay, 
days 



















All PIMS-TS patients had evidence of a marked 
inflammatory state (Table 2). CRP level was 
significantly elevated [median, 201 mg/L (IQR,  
127-301)] in 9/10 patients. IL-6 [median, 78 pg/mL 
(IQR, 57-206)], and ferritin [850 ng/mL (IQR, 540-
1230)] were also raised, along with neutrophilia, and 
lymphopenia. NT-proBNP concentrations were 
elevated in 100% (10/10) patients showing severe 
myocardial dysfunction. Anemia, transaminitis and 
increased LDH concentration were as observed in 
some subjects. Creatinine remained within the normal 
range for all. Hyponatremia was a marked feature in 
all 10 patients. 
 
Comparison of Laboratory features of PIMS-TS with KD: 
Patients with PIMS-TS were generally older than 
those with KD and higher white blood cell count, 
neutrophil count, and other inflammatory markers 
such as CRP and ferritin, as well as more profound 
lymphopenia, and hyponatremia. The potassium level 
was also lower (Table 3). They also tended to have 
lower platelet counts, lower protein, and albumin 
levels. Alanine aminotransferase activity and 
hemoglobin were similar between those with PIMS-
TS and KD. Comparison values were not available for 
LDH and IL-6. 
 
Serial measurements of C-Reactive Protein 
The CRP level at the time of admission (baseline) 
was appreciably higher in the PIMS-TS cases 
compared to either KD or active COVID-19 case  
(Fig. 1), which decreased gradually with therapy. The 
patient that was referred to another hospital for 
cardiac management, had an initial IL-6 of  
74.2 pg/mL (day 1) and decreased to 11.6 pg/mL  
(day 12). Another patient diagnosed with KD having 
active SARS-CoV-2 infection (Case 11) showed a 
higher CRP compared to other two KD cases (Cases 12 
and 13). 
Table 2 — Laboratory features of PIMS-TS children 
n=10 Values 
(baseline, on admission) 
Normal Values Number of PIMS-TS cases with: 
Hemoglobin, g/dL 10.2 (9.4-10.7) > 12 Hemoglobin <9 
n= 1 (10%) 
White blood cell count ×1000 /mm3 9.5 (7.3-18.5) 4.5 - 13.5 WBC >13.5 × 1000 /mm3 
n= 4 (40%) 
Neutrophil % 80 (68-84) - - 
Lymphocyte % 14 (11-24) - - 
Platelet count, /mm3 1,69,000 (1,18,000-2,57,000) 1,50,000 - 4,00,000 Platelets <1,50,000 
n= 5 (50%) 
Albumin, g/dL 3.0 (2.7-3.4) >3.5 Albumin  ≤3 
n= 6 (60%) 
ALT, U/L 27 (17-52) <35 ALT  > 40 
n= 3 (30%) 
Creatinine, mg/dL 0.46 (0.40-0.56) 0.29 -0.47 (Age specific, 
for 5 - 7 years child) 
Creatinine × 2 ULN 
n= 0 (none) 
Sodium, mmol/L 129.5 (127.0-131.3) >135 Sodium < 135 
n= 10 (100%) 
Lactate Dehyrogenase, U/L 283 (238-387) 120 - 300 Lactate Dehyrogenase, >300 
n= 1 (10%) 
C-Reactive Protein, mg/L 201 (127-301) <5 C-Reactive Protein  >100 
n= 9 (90%) 
Ferritin, ng/mL 856 (540-1230) <120 Ferritin  >500 
n= 8 (80%) 
NT-ProBNP, pg/mL 4736 (1110-24451) <150 NT-ProBNP >400  
n= 9 (90%) 
Interleukin-6, pg/mL 78 (57-206) <7 Interleukin-6 > 80 
n= 4 (40%) 
Data are median (interquartile range), n = number, is the total number of patients with available data. Dashes indicate not applicable. 
NT-proBNP, N-terminal pro-B-type natriuretic peptide 





There has been an upsurge in the admission of 
pediatric patients with Kawasaki like features 
following the COVID-19 pandemic and one of the 
first alerts came from the Italian pediatric intensivists 
at Bergamo
18
 describing a new unusual inflammatory 
disorder in children who had no active SARS-CoV-2 
infection, but were positive for increased antibodies to 
the virus. These children tended to be older and sicker 
compared to classical KD manifestations and needed 
intensive care support. With RCPCH (The Royal 
College of Paediatrics and Child Health), WHO and 
CDC, later, defining this disorder as PIMS-TS or 
MISC, various early centers of the pandemic in India 
Table 3 — Comparison of Laboratory features of PIMS-TS with KD 
Median Values (Inter quartile ranges) of: PIMS-TS (n=10) KD (n=19) P value 
Hemoglobin, g/dL 10.2 (9.4-10.7) 9.6 (8.7-10.3) 0.1434 
White blood cell count ×1000 /mm3 9.5 (7.3-18.5) 19.9 (13.5-24.0) 0.01 
Neutrophil % 80 (68-84) 64 (60-69) 0.006 
Lymphocyte % 14 (11-24) 30 (25-36) 0.002 
Platelet count, /mm3 1, 69, 000 (1, 18, 000-2, 57, 000) 5, 36, 000 (3, 69, 000-6, 66, 000) 0.0002 
Protein Total, g/dL 5.4 (5.1-6.2) 6.1 (5.7-7.1) 0.04 
Albumin, g/dL 3.0 (2.7-3.4) 3.5 (3.33.6) 0.04 
ALT, U/L 27 (17-52) 27 (17-47) 0.96 
AST, U/L 33 (23-55) 38 (28-51) 0.52 
Creatinine, mg/dL 0.46 (0.40-0.56) 0.26 (0.20-0.32) <0.001* 
Sodium, mmol/L 129.5 (127.0-131.3) 134 (131.8-135) 0.0006 
Potassium, mmol/L 3.50 (3.35-4.00) 4.30 (4.00-4.53) 0.009 
C-Reactive Protein, mg/L 201 (127-301) 95 (54-100) 0.001 
Ferritin, ng/mL 856 (540-1230) 267 (175-275) 0.005 
NT-ProBNP, pg/mL 4736 (1110-24451) 333 (169-557) 0.0005 




Fig.1 — CRP levels (mg/L) measured serially over time in children presenting with PIMS (Cases 1-10), KD (Cases 11-13)  
Case 14 line graph (red) are serial values in a SLE patient with active COVID-19 infection and hypercytokinemia 











. An article in the 
Times of India dated September 17, 2020 states that 
pediatric hospitals of Kolkata have started to receive 
PIMS-TS cases from the middle of August, 2020 and 
cases are increasing with time
21
. Laboratory markers 
have been the hallmark to diagnose, and monitor 
COVID-19 and now in PIMS-TS cases too, especially 
in the evaluation of the inflammatory state of the 
patient
22
. This study has shown that several routinely 
investigated tests such as CRP have become an 
effective confirmatory marker to diagnose PIMS-TS. 
These markers with clinical symptoms have thrown 
up many differences with KD. CRP level was 
reported to be extremely high in PIMS-TS
23
 and level 
above 150 mg/L can clearly indicate towards PIMS-
TS. While the level in KD was much lower. CRP is 
inexpensive and can be serially investigated to 
monitor the efficacy of therapy. While our study did 
not report ESR, this marker has also been quite 
effective in monitoring inflammation.  
Thus children admitted with features of viral 
infections such as KD, TSS or PIMS-TS should 
undergo basic laboratory investigations including of 
complete blood count (CBC), CRP, renal function 
tests, liver function tests, electrolytes estimation, urine 
routine examination, blood cultures along with 
COVID-19 RTPCR and serology. Though common 
findings are anemia, hypoalbuminemia, transaminitis, 
high WBC counts, neutrophilia, and lymphopenia
14-17
, 
documentation of anemia and transaminitis in this 
cohort was failed. However, hyponatremia was 
reasonably asserted. No patient was reported to have 
acute kidney injury and creatinine level was within a 




Once diagnosed, the tier 2 investigations such as 
ferritin, IL-6, procalcitonin, LDH, D-Dimer, 
fibrinogen, blood gas analysis, blood lactate levels, 
troponin and NT-Pro-BNP, septic and viral screen, 
along with other radiological investigations would be 
helpful to confirm the inflammatory state along with 
the development of other manifestations in the child 
such as hypercoagulable state, macrophage activation 
syndrome (MAS), shock, and myocarditis and to 
monitor therapy such as the use of IL-6 inhibitor-
tocilizumab
13
. High ferritin and IL-6 levels in this 
study indicated an intense inflammatory state. High 
ferritin level possibly suggests interplay with  
MAS. Determination of IL-6 level at the time of 




One of the most important biomarkers of PIMS-TS 
is NT-Pro-BNP, a marker of heart failure. In our study 
all PIMS-TS patients had significantly elevated  
NT-Pro-BNP levels, as observed in other study
16
. 
Further, SARS-CoV-2 IgG is positively correlated 
with cardiac injury markers such as troponin and 
CKMB is indicative of clinical worsening and shock. 
As observed in earlier studies, cases of PIMS-TS 
children were older than those with KD, and with 
starkly different laboratory features
23,24
. Children with 
PIMS-TS tended to have more intense inflammation, 
namely higher levels of CRP, and ferritin, and had 
higher levels of markers of myocardial affliction such 
as NT-ProBNP. These patients have higher 
neutrophils, lower lymphocytes, lower platelets; and 
also lower protein, albumin, sodium, and potassium 
levels. This study however did not record high WBC 
counts and could be ascribed to some patients having 
a progressive course of the condition where values  
may decrease.   
Comparison of PIMS-TS with acute COVID-19 
shows that these are quite different
13
. In this study, 
patients with active SARS-CoV-2 infection had lower 
baseline and peak CRP levels compared to PIMS-TS 
cases (see Fig 1) during the course of the disease. The 
hyperinflammatory response of PIMS-TS differs from 
the cytokine release syndrome of severe acute 
COVID-19. While there is a commonality with KD, 
but also differs from this condition with respect to 
cytokines and biomarkers of endothelial damage 
14,25
.  
The study is limited by the number of patients 
and marker values may not accurately represent the 
cohort’s features. Nonetheless, marker trends were 
similar to findings made by other study groups and 
point to a specific emerging pattern. The current 
study provides information on the comparison of 
laboratory features of PIMS and KD; which may be 
valuable to clinicians to assist in diagnosing and 




PIMS-TS/MIS-C is a new disease entity seen in 
children and adolescents several weeks after SARS-
CoV-2 infection. It has a typical biomarker profile 
consisting of severely elevated inflammatory markers 
such as CRP, IL-6, WBC counts, Ferritin, and LDH, 
along with anemia, hyponatremia and raised NT-
ProBNP that can help to differentiate it from KD with 




similar clinical presentation. Overall mortality of 
PIMS-TS/MIS-C is rare and CRP serves as a good 
prognostic indicator of therapeutic response.  
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